(Q37792471)

23 August 2017

title

Interleukin-6: from identification of the cytokine to development of targeted treatments (English)

1 reference

23 August 2017

Interleukin-6: From identification of the cytokine to development of targeted treatments (English)

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

20 July 2024

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20869898

20 July 2024

author name string

Eric Assier

1

1 reference

23 August 2017

Marie-Christophe Boissier

2

1 reference

23 August 2017

Jean-Michel Dayer

3

1 reference

23 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20869898

20 July 2024

publication date

24 September 2010

1 reference

full work available at URL

23 August 2017

https://api.elsevier.com/content/article/PII:S1297319X10001983?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

https://api.elsevier.com/content/article/PII:S1297319X10001983?httpAccept=text/plain

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

20 July 2024

1 reference

23 August 2017

volume

77

1 reference

23 August 2017

issue

6

1 reference

23 August 2017

page(s)

532-536

1 reference

Cell to cell interaction in the immune response. I. Hemolysin-forming cells in neonatally thymectomized mice reconstituted with thymus or thoracic duct lymphocytes

23 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Thymus-marrow immunocompetence. 3. The requirement for living thymus cells.

20 July 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Absence of antiviral activity in recombinant B cell stimulatory factor 2 (BSF-2)

20 July 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas

20 July 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells

20 July 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Recombinant human B cell stimulatory factor 2 (BSF-2/IFN-beta 2) regulates beta-fibrinogen and albumin mRNA levels in Fao-9 cells

20 July 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Cloning of cDNA encoding the murine IgG1 induction factor by a novel strategy using SP6 promoter

20 July 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin

20 July 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Impaired immune and acute-phase responses in interleukin-6-deficient mice.

20 July 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice.

20 July 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Serum levels of interleukin-6 and acute phase responses

20 July 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

CRP as a mediator of disease

20 July 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

The pathophysiologic roles of interleukin-6 in human disease

20 July 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

IL-4-supported induction of cytolytic T lymphocytes requires IL-2 and IL-6.

20 July 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Increased osteoclast development after estrogen loss: mediation by interleukin-6

20 July 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis

20 July 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo

20 July 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae

20 July 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Role for osteoprotegerin in rheumatoid inflammation

20 July 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

In Vivo Neutralization of Human IL-6 (hIL-6) Achieved by Immunization of hIL-6-Transgenic Mice with a hIL-6 Receptor Antagonist

20 July 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Interleukin-6 modulates production of T lymphocyte–derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis

20 July 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Cartilage homeostasis in health and rheumatic diseases

20 July 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation.

20 July 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Interleukin-6: discovery of a pleiotropic cytokine

20 July 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Interleukin-6 and its receptor in autoimmunity

20 July 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis

20 July 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody

20 July 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Interleukin-6 and rheumatic diseases

20 July 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism.

20 July 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes

20 July 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity

20 July 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Current aspects of anti-CD20 therapy in rheumatoid arthritis

20 July 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells

20 July 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation

20 July 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Anemia of inflammation: the cytokine-hepcidin link

20 July 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin

20 July 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells

20 July 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion

20 July 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Prostaglandin E2: igniting the fire

20 July 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion

20 July 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Shifting the imbalance from Th1/Th2 to Th17/treg: the changing rheumatoid arthritis paradigm

20 July 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Pharmacokinetics of interleukin-6 during therapy with anti-interleukin-6 monoclonal antibodies: enhanced clearance of interleukin-6 by a combination of three anti-interleukin-6 antibodies

20 July 2024

52

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system

20 July 2024

53

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

20 July 2024

54

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial

20 July 2024

55

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor

20 July 2024

56

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

20 July 2024

57

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis

20 July 2024

58

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

20 July 2024

59

1 reference

https://api.crossref.org/works/10.1016/J.JBSPIN.2010.07.007

20 July 2024

Identifiers

1 reference

23 August 2017

1 reference